Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 890-895

  Roussou, Maria ^a   Kastritis, Efstathios ^a   Migkou, Magdalini ^a   Psimenou, Erasmia ^a   Grapsa, I Irini ^a   Matsouka, Charis ^a   Barmparousi, Despina ^a   Terpos, Evangelos ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bortezomib; Myeloma; Renal failure

Indexed keywords

BORTEZOMIB; CREATINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; INFECTION; KIDNEY FAILURE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVERSAL REACTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

BORONIC ACIDS; HUMANS; KIDNEY FAILURE; MULTIPLE MYELOMA; PYRAZINES; TREATMENT OUTCOME;

EID: 46749152199     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801930506     Document Type: Article

References (24)

1. Alexanian, R., Barlogie, B. and Dixon, D. (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med, 150, pp. 1693-1695.
2. Blade, J., Fernandez-Llama, P., Bosch, F., Montoliu, J., Lens, X. M. and Montoto, S. (1998) Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med, 158, pp. 1889-1893.
3. Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q. and Dispenzieri, A. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, pp. 21-33.
4. Blade, J., Fernandez-Llama, P., Bosch, F., Montoliu, J., Lens, X. M. and Montoto, S. (1998) Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med, 158, pp. 1889-1893.
5. Knudsen, L. M., Hippe, E., Hjorth, M., Holmberg, E. and Westin, J. (1994) Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol, 53, pp. 207-212.
6. Knudsen, L. M., Hjorth, M. and Hippe, E. (2000) Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol, 65, pp. 175-181.
7. Sakhuja, V., Jha, V., Varma, S., Joshi, K., Gupta, K. L. and Sud, K. (2000) Renal involvement in multiple myeloma: A 10-year study. Ren Fail, 22, pp. 465-477.
8. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S. and Irwin, D. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348, pp. 2609-2617.
9. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D. and Richardson, P. G. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 127, pp. 165-172.
10. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A. and Facon, T. (2005) Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352, pp. 2487-2498.
11. Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J. and Allred, T. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, pp. 3058-3065.
12. Terpos, E., Anagnostopoulos, A., Heath, D., Kastritis, E., Christoulas, D. and Anagnostopoulos, N. (2006) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of dickkopf-1, RANKL, MIP-1α and angiogenic cytokines. Blood (suppl.), 108
13. Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N. and Callea, V. (2007) Italian multiple myeloma network, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 109, pp. 2767-2772.
14. Mateos, M. V., Hernandez, J. M., Hernandez, M. T., Gutierrez, N. C., Palomera, L. and Fuertes, M. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase1/2study. Blood, 108, pp. 2165-2172.
15. Harousseau, J. L., Attal, M., Leleu, X., Troncy, J., Pegourie, B. and Stoppa, A. M. (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica, 91, pp. 1498-1505.
16. Oakervee, H. E., Popat, R., Curry, N., Smith, P., Morris, C. and Drake, M. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol, 129, pp. 755-762.
17. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B. and Gahrton, G. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 102, pp. 1115-1123.
18. Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R. and Srkalovic, G. (2005) SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 103:6, pp. 1195-1200.
19. Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C. and Lonial, S. (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood, 109:6, pp. 2604-2606.
20. Onitilo, A. A., Engle, J., Olatosi, B. and Fagbemi, S. (2007) Community experience with bortezomib in patients with multiple myeloma. Am J Hematol, 82, pp. 637-639.
21. Malani, A. K., Gupta, V. and Rangineni, R. (2006) Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol, 116:4, pp. 255-258.
22. Nozza, A., Siracusano, L. and Armando, S. (2006) Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther, 28:6, pp. 953-959.
23. Ludwig, H., Drach, J., Graf, H., Lang, A. and Meran, J. G. (2007) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica, 92, pp. 1411-1414.
24. Mallick, N. P., Olujohungbe, A. and Drayson, M. T. (1998) Renal impairment in myeloma: Time for a reappraisal?. Nephrol Dial Translant, 13, pp. 30-32.